ArticleFrontiers in microbiology2025
PacBio high-fidelity near full-length genome sequencing for HIV-1 quasispecies: methodological framework and validation.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ion Torrent Genexus as a Fast and Reliable Solution for HIV-1 Drug Resistance Testing: Comparison with the GeneStudio S5 Workflow.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to develop an optimized sequencing workflow for HIV-1 near full-length genome (NFLG) quasispecies, integrating the PacBio Revio platform with a streamlined bioinformatics pipeline to enable precise characterization of the genetic heterogeneity and dynamic evolution of HIV-1 quasispecies. To this end, the HIV-1 NFLG was divided into three segments for high-fidelity amplification and PacBio sequencing. This method achieved stable amplification (positivity rate >80%) in samples with a viral load >1,000 copies/mL and demonstrated applicability to China's five major epidemic strains and unique recombinant forms (URFs). The adoption of sample-specific asymmetric barcode sequences improved cost-effectiveness, enabling efficient sequencing of 300 to 1,000 samples per sequencing cell. The entire amplification-sequencing workflow exhibited minimal systematic errors (recombination rate <3.5%, average base variation rate <0.1%). Following bioinformatic processing including filtering, clustering, and screening, the sequencing data yielded multiple accurate viral quasispecies sequences with their approximate abundance profiles. Validation studies demonstrated excellent concordance with results from conventional single-genome amplification (SGA) and Sanger sequencing, while showing superior performance in quasispecies-level dual infection detection and recombinant pattern identification. In conclusion, this study developed a PacBio HiFi-based sequencing workflow for HIV-1 NFLG quasispecies, which exhibits robust high sensitivity, accuracy, and reproducibility. This approach provides a powerful tool for deepening understanding of HIV-1 evolution, dissecting genetic diversity, tracing transmission chains, and facilitating precision antiretroviral therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.